Physician profile
Paul Jutte
NPI 1114540317
$2,477.94
in general payments reported to CMS, 2019-2025
22 companies · $818 in 2025
The $818 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.89 · 2022: $337 · 2023: $688 · 2024: $600 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,105.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $417.89 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $334.70 | 2021-2025 | Ingrezza |
| Abbvie INC. | $276.76 | 2023-2024 | |
| Alkermes, INC. | $187.38 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $168.87 | 2023-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $166.47 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $133.08 | 2024-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $117.28 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Supernus Pharmaceuticals, INC. | $112.08 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $86.63 | 2023-2025 | Loreev Xr, Gralise |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.51 | 2024-2025 | Caplyta |
| Corium, LLC | $69.44 | 2022-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $64.33 | 2022-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $62.88 | 2023-2025 | Trintellix |
| Neos Therapeutics, LP | $61.94 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $34.84 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $32.91 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $18.62 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $17.21 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $14.54 | 2023 | Xelstrym |
| Owp Pharmaceuticals, INC. | $13.83 | 2022 | |
| Biogen, INC. | $13.75 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jutte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.